

REMARKS

The Applicants are submitting this amendment because they have noted a discrepancy in the Examiner's Amendment mailed April 21, 2005 and the undersigned's notes of the March 11, 2005 telephone interview. In the Amendment the Examiner replaced "n is 0 to 3" with "n is 2 or 3" [emphasis added]. The Applicants' notes from the March 11, 2005 telephone interview, a copy of which is enclosed, indicate that the proposal, as the undersigned understood it, was to replace "n is 0 to 3" with "n is 1 to 3". Applicants respectfully submit that this amendment is supported by the application as filed and is also free of the prior art. Thus, this change does not constitute new matter and does not require any search. Its entry is respectfully requested.

The Commissioner is authorized to charge any fee deficiencies or credit any overpayments associated with this submission to the NIXON PEABODY LLP Deposit Account No. 50-0850.

Date: 7/20/05

Customer No. 50828

Respectfully submitted,




David S. Resnick (Reg. No. 34,235)
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110
(617) 345-6057

APPLICANTS' NOTES
RE: 3/11/05 TELEPHONE
INTERVIEW W/ EXAMINER

CLAIMS

1. (CURRENTLY AMENDED) A composition compound of the formula



, wherein R is $(CH_2)_nR'$, where n is 0 to 3, R' is NH_2 , OH or SH , and its or a pharmaceutically acceptable salts salt thereof.

2. (ORIGINAL) The ^{compound} composition of claim 1, wherein R' is $(CH_2)_2NH_2$.
3. (CURRENTLY AMENDED) A method of inhibiting angiogenesis in a mammal having undesired angiogenesis comprising administering an effective amount of the composition compound of claim 1.